source
- Blackstone invests $250 million in Anagram to address cystic fibrosis complicationBlackstone Life Sciences announced a $250 million investment in Anagram, a biotech focused on cystic fibrosis complications. The funding is part of one of the largest private investment funds in t…
- FDA holds Type A meeting with Atara after CRL issued for tabelecleucel in EBV-positive PTLDThe FDA and Atara Biotherapeutics met in a Type A meeting to discuss the complete response letter (CRL) that the agency issued for the biologics license application of tabelecleucel, a therapy for…